Publicacións nas que colabora con Andres Iñiguez Romo (25)

2023

  1. Changes in circulating ApoJ-Glyc levels in patients with suspected acute coronary syndrome: The EDICA trial

    International Journal of Cardiology, Vol. 391

  2. Trends in cardiovascular care in the National Health System in Spain. Data from the RECALCAR project 2011-2020

    Revista Espanola de Cardiologia, Vol. 76, Núm. 7, pp. 519-530

2022

  1. 6-Month Outcomes of the TricValve System in Patients With Tricuspid Regurgitation: The TRICUS EURO Study

    JACC: Cardiovascular Interventions, Vol. 15, Núm. 13, pp. 1366-1377

  2. Complete revascularization optimizes patient outcomes in multivessel coronary artery disease: Data from the e-Ultimaster registry

    Catheterization and Cardiovascular Interventions, Vol. 99, Núm. 4, pp. 961-967

  3. Rationale and design of the Dapagliflozin after Transcatheter Aortic Valve Implantation (DapaTAVI) randomized trial

    European Journal of Heart Failure, Vol. 24, Núm. 3, pp. 581-588

  4. Telemedicine consultation and evolutionary model in outpatient care of cardiovascular processes

    REC: CardioClinics, Vol. 57, Núm. 2, pp. 97-106

2021

  1. Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

    Journal of the American College of Cardiology, Vol. 78, Núm. 5, pp. 421-433

2020

  1. Incidence, predictors and prognostic impact of intracranial bleeding within the first year after an acute coronary syndrome in patients treated with percutaneous coronary intervention

    European Heart Journal: Acute Cardiovascular Care, Vol. 9, Núm. 7, pp. 764-770

  2. P2Y12 inhibitors in acute coronary syndrome patients with renal dysfunction: an analysis from the RENAMI and BleeMACS projects

    European heart journal. Cardiovascular pharmacotherapy, Vol. 6, Núm. 1, pp. 31-42

2019

  1. Efecto de la técnica de implantación en los resultados en pacientes tratados con armazón bioabsorbible en diferentes escenarios clínicos

    REC: Interventional Cardiology, Vol. 1, Núm. 2, pp. 83-91

  2. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

    The Lancet Diabetes and Endocrinology, Vol. 7, Núm. 8, pp. 618-628

  3. Requisitos y sostenibilidad de los programas de ICP primaria en España en el IAMCEST.: Documento de consenso de SEC, AEEC y SEMES

    REC: Interventional Cardiology, Vol. 1, Núm. 2, pp. 108-119

2018

  1. Alirocumab and cardiovascular outcomes after acute coronary syndrome

    New England Journal of Medicine, Vol. 379, Núm. 22, pp. 2097-2107

  2. Development and external validation of a post-discharge bleeding risk score in patients with acute coronary syndrome: The BleeMACS score

    International Journal of Cardiology, Vol. 254, pp. 10-15

  3. Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry

    Indian Heart Journal, Vol. 70, Núm. 6, pp. 828-835

2017

  1. Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention

    Journal of the American College of Cardiology, Vol. 69, Núm. 2, pp. 176-185

  2. Evolocumab and clinical outcomes in patients with cardiovascular disease

    New England Journal of Medicine, Vol. 376, Núm. 18, pp. 1713-1722

2016

  1. Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELD-AF and treated with vitamin K antagonists

    British Journal of Haematology, Vol. 174, Núm. 4, pp. 610-623

  2. NT-proBNP for risk stratification of nonagenarian patients with severe symptomatic aortic stenosis

    International Journal of Cardiology, Vol. 223, pp. 785-786

  3. On the Way to a Better Use of Anticoagulants in Nonvalvular Atrial Fibrillation. Proposed Amendment to the Therapeutic Positioning Report UT/V4/23122013

    Revista Espanola de Cardiologia, Vol. 69, Núm. 6, pp. 551-553